Evidence map›Paper›PMID 23150958›Full record

ArticleThe New England journal of medicine2012

Differentiation of reinfection from relapse in recurrent Lyme disease.

Robert B Nadelman, Klára Hanincová, Priyanka Mukherjee, Dionysios Liveris, John Nowakowski, Donna McKenna, Dustin Brisson, Denise Cooper, Susan Bittker, Gul Madison and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The New England journal of medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 3 pooled it
11.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 134 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Guideline
  4. Trial
  5. Article
  6. Article
  7. SIRI+Q model with a limited capacity of isolation.Theory in biosciences = Theorie in den Biowissenschaften · 2025
    Article
  8. Article
  9. Review
  10. Suppression of host humoral immunity byInfection and immunity · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Development of an mRNA-lipid nanoparticle vaccine against Lyme disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Robert B NadelmanDivision of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA. robert_nadelman@nymc.edu
Klára Hanincová
Priyanka Mukherjee
Dionysios Liveris
John Nowakowski
Donna McKenna
Dustin Brisson
Denise Cooper
Susan Bittker
Gul Madison
Diane Holmgren
Ira Schwartz
Gary P Wormser
Office of Infectious Diseases · USNew York Medical College · USUniversity of Pennsylvania · US

Funding

DETERMINANTS OF B BURGDORFERI HEMATOGENOUS DISSEMINATIONR01AI045801 · NIAID · NEW YORK MEDICAL COLLEGE · PI SCHWARTZ, IRA S. · 1999 to 2015
$4.9M
NUCLEIC ACID-BASED DIANOSTIC PROBES FOR LYME DISEASER01AR041511 · NIAMS · NEW YORK MEDICAL COLLEGE · PI SCHWARTZ, IRA S. · 1991 to 2009
$4.1M
NIAID NIH HHS AI45801NIAID NIH HHS R01 AI045801NIAMS NIH HHS AR41511NIAMS NIH HHS R01 AR041511
6 · The paper itself

Abstract

backgroundErythema migrans is the most common manifestation of Lyme disease. Recurrences are not uncommon, and although they are usually attributed to reinfection rather than relapse of the original infection, this remains somewhat controversial. We used molecular typing of Borrelia burgdorferi isolates obtained from patients with culture-confirmed episodes of erythema migrans to distinguish between relapse and reinfection.

methodsWe determined the genotype of the gene encoding outer-surface protein C (ospC) of B. burgdorferi strains detected in cultures of skin or blood specimens obtained from patients with consecutive episodes of erythema migrans. After polymerase-chain-reaction amplification, ospC genotyping was performed by means of reverse line-blot analysis or DNA sequencing of the nearly full-length gene. Most strains were further analyzed by determining the genotype according to the 16S-23S ribosomal RNA intergenic spacer type, multilocus sequence typing, or both. Patients received standard courses of antibiotics for erythema migrans.

resultsB. burgdorferi isolates obtained from 17 patients who received a diagnosis of erythema migrans between 1991 and 2011 and who had 22 paired episodes of this lesion (initial and second episodes) were available for testing. The ospC genotype was found to be different at each initial and second episode. Apparently identical genotypes were identified on more than one occasion in only one patient, at the first and third episodes, 5 years apart, but different genotypes were identified at the second and fourth episodes.

conclusionsNone of the 22 paired consecutive episodes of erythema migrans were associated with the same strain of B. burgdorferi on culture. Our data show that repeat episodes of erythema migrans in appropriately treated patients were due to reinfection and not relapse. (Funded by the National Institutes of Health and the William and Sylvia Silberstein Foundation.).

Indexed as

AdultAntigens, BacterialBacterial Outer Membrane ProteinsBorrelia burgdorferiDiagnosis, DifferentialDNA, BacterialGenotypeHumansLyme DiseaseRecurrenceSequence Analysis, DNAAntigens, BacterialBacterial Outer Membrane ProteinsDNA, BacterialOspC protein

Identifiers

PMID23150958
PMCPMC3526003
OpenAlexW2150694421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.